Summary
Boston Scientific Corporation (BSX) reported its first-quarter 2012 financial results, showing a decrease in net sales to $1.866 billion from $1.925 billion in the prior year, primarily driven by declines in their Cardiac Rhythm Management (CRM) and Interventional Cardiology businesses. Despite the sales dip, the company reported net income of $113 million ($0.08 per share) for the quarter, a significant improvement from $46 million ($0.03 per share) in Q1 2011. This improvement was partly due to a substantial goodwill impairment charge of $697 million recorded in the first quarter of 2011, which did not recur in 2012. Operating activities generated positive cash flow of $212 million in Q1 2012, a marked improvement from a cash outflow of $97 million in Q1 2011. The company also highlighted progress in its strategic acquisitions and restructuring initiatives, aiming for long-term operational efficiency and growth. Investors will note the company's continued focus on strategic growth areas, evidenced by the planned acquisition of Cameron Health, Inc., a developer of subcutaneous implantable cardioverter defibrillators. While sales faced headwinds in certain segments, the company demonstrated improved profitability and cash generation. The company also achieved investment-grade ratings from all three major credit rating agencies, indicating a strengthening financial profile. However, ongoing legal matters and potential impacts from the European sovereign debt crisis warrant continued investor attention.
Financial Highlights
48 data points| Revenue | $1.87B |
| Cost of Revenue | $631.00M |
| Gross Profit | $1.24B |
| SG&A Expenses | $659.00M |
| Operating Expenses | $1.04B |
| Operating Income | $196.00M |
| Interest Expense | $69.00M |
| Net Income | $113.00M |
| EPS (Basic) | $0.08 |
| EPS (Diluted) | $0.08 |
| Shares Outstanding (Basic) | 1.45B |
| Shares Outstanding (Diluted) | 1.45B |
Key Highlights
- 1Net sales decreased by 3% to $1.866 billion compared to $1.925 billion in Q1 2011, primarily due to declines in the Cardiac Rhythm Management (CRM) and Interventional Cardiology segments.
- 2Net income increased significantly to $113 million ($0.08 per share) in Q1 2012 from $46 million ($0.03 per share) in Q1 2011, aided by the absence of a large goodwill impairment charge seen in the prior year.
- 3Operating cash flow turned positive, generating $212 million in Q1 2012, a substantial improvement from using $97 million in Q1 2011, driven partly by lower litigation-related outflows.
- 4The company announced plans to acquire Cameron Health, Inc., a developer of subcutaneous implantable cardioverter defibrillators, signaling investment in innovative medical technologies.
- 5Boston Scientific achieved investment-grade credit ratings from all three major rating agencies (Moody's, S&P, and Fitch), reflecting improved financial fundamentals.
- 6Selling, General, and Administrative (SG&A) expenses increased by 11% to $659 million, largely due to investments in global expansion and rollout of acquired products.
- 7Restructuring charges for Q1 2012 were $10 million, down from $38 million in Q1 2011, reflecting ongoing efforts to improve operational efficiency.